+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atopic Dermatitis - Pipeline Review, H2 2019

  • ID: 4866602
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 597 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abate Med Inc
  • Azitra Inc
  • F. Hoffmann-La Roche Ltd
  • Krystal Biotech Inc
  • NovaCell Technology Inc
  • Seelos Therapeutics Inc
  • MORE
Atopic Dermatitis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 47, 25, 3, 57, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abate Med Inc
  • Azitra Inc
  • F. Hoffmann-La Roche Ltd
  • Krystal Biotech Inc
  • NovaCell Technology Inc
  • Seelos Therapeutics Inc
  • MORE
Introduction
Atopic Dermatitis (Atopic Eczema) - Overview
Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Drug Profiles
Atopic Dermatitis (Atopic Eczema) - Dormant Projects
Atopic Dermatitis (Atopic Eczema) - Discontinued Products
Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 10: Number of Products under Development by Universities/Institutes, H2 2019
Table 11: Products under Development by Companies, H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Table 22: Products under Development by Universities/Institutes, H2 2019
Table 23: Number of Products by Stage and Target, H2 2019
Table 24: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 25: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 26: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 27: Number of Products by Stage and Mechanism of Action, H2 2019
Table 28: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 29: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 31: Number of Products by Stage and Route of Administration, H2 2019
Table 32: Number of Products by Stage and Molecule Type, H2 2019
Table 33: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H2 2019
Table 34: Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2019
Table 35: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2019
Table 36: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, H2 2019
Table 37: Atopic Dermatitis (Atopic Eczema) - Pipeline by Afecta Pharmaceuticals Inc, H2 2019
Table 38: Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, H2 2019
Table 39: Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergan Plc, H2 2019
Table 40: Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, H2 2019
Table 41: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, H2 2019
Table 42: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, H2 2019
Table 43: Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, H2 2019
Table 44: Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, H2 2019
Table 45: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Inc, H2 2019
Table 46: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
Table 47: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Table 48: Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, H2 2019
Table 49: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Table 50: Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, H2 2019
Table 51: Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, H2 2019
Table 52: Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, H2 2019
Table 53: Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, H2 2019
Table 54: Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, H2 2019
Table 55: Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, H2 2019
Table 56: Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, H2 2019
Table 57: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 58: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Table 59: Atopic Dermatitis (Atopic Eczema) - Pipeline by Botanix Pharmaceuticals Ltd, H2 2019
Table 60: Atopic Dermatitis (Atopic Eczema) - Pipeline by Calcico Therapeutics Ltd, H2 2019

List of Figures
Figure 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3
  • Abate Med Inc
  • AbbVie Inc
  • Abeome Corp
  • Aclaris Therapeutics Inc
  • Afecta Pharmaceuticals Inc
  • Akaal Pharma Pty Ltd
  • Allergan Plc
  • Almirall SA
  • Amgen Inc
  • Amorepacific Corp
  • AOBiome LLC
  • Apimeds Inc
  • Arcutis Inc
  • Arena Pharmaceuticals Inc
  • Arrien Pharmaceuticals LLC
  • Asana BioSciences LLC
  • Aslan Pharmaceuticals Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atrapos Therapeutics LLC
  • Azitra Inc
  • Bausch Health Companies Inc
  • Biomimetix JV LLC
  • Blueberry Therapeutics Ltd
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Botanix Pharmaceuticals Ltd
  • Calcico Therapeutics Ltd
  • Celgene Corp
  • ChironWells GmbH
  • Chugai Pharmaceutical Co Ltd
  • Clayton Biotechnologies Inc
  • Clevexel Pharma SAS
  • CSA Biotechnologies LLC
  • Cutanea Life Sciences Inc
  • Daiichi Sankyo Co Ltd
  • Dermata Therapeutics LLC
  • Dermavant Sciences Inc
  • DermBiont Inc
  • Devonian Health Group Inc
  • DongKoo Bio & Pharma Co Ltd
  • DURECT Corp
  • EHL Bio Co Ltd
  • Eli Lilly and Co
  • Evelo Biosciences Inc
  • Evotec SE
  • F. Hoffmann-La Roche Ltd
  • Fountain Biopharma Inc
  • Galapagos NV
  • Galderma SA
  • General Regeneratives Shanghai Ltd
  • GI Innovation Co Ltd
  • GlaxoSmithKline Plc
  • Helix BioMedix Inc
  • Hill Dermaceuticals Inc
  • Hoth Therapeutics Inc
  • Huons Co Ltd
  • Ichnos Sciences Inc
  • Immune Pharmaceuticals Inc
  • Incyte Corp
  • Inflamalps SA
  • Innovation Pharmaceuticals Inc
  • Innovimmune Biotherapeutics Inc
  • Japan Tobacco Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • JW Pharmaceutical Corp
  • Kang Stem Biotech Co Ltd
  • Kine Sciences
  • Kiniksa Pharmaceuticals Corp
  • KoBioLabs Inc
  • Krystal Biotech Inc
  • Kv1.3 Therapeutics
  • Kymab Ltd
  • Kyowa Kirin Co Ltd
  • Larix Bioscience LLC
  • Lead Pharma Holding BV
  • Lemonex Inc
  • Leo Pharma AS
  • Lipid Biologics LLC
  • Lypanosys Pte Ltd
  • Madam Therapeutics BV
  • Matrisys Bioscience Inc
  • MC2 Therapeutics AS
  • Medicenna Therapeutics Corp
  • Micreos BV
  • Nektar Therapeutics
  • Nepsone ehf
  • Neuracle Science Co Ltd
  • NeuroCycle Therapeutics GmbH
  • Next Science Ltd
  • NovaCell Technology Inc
  • Novan Inc
  • Novartis AG
  • Oasis Pharmaceuticals LLC
  • OliX Pharmaceuticals Inc
  • Ondek Pty Ltd
  • Orbis Biosciences Inc
  • Otsuka Holdings Co Ltd
  • Pantherics Inc
  • Pfizer Inc
  • PHI Therapeutics Inc
  • Polyrizon Ltd
  • Portola Pharmaceuticals Inc
  • Provectus Biopharmaceuticals Inc
  • Pyramid Biosciences Inc
  • Qurient Co Ltd
  • Ralexar Therapeutics Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Ribomic Inc
  • SCM lifescience Co Ltd
  • Seelos Therapeutics Inc
  • Servatus Ltd
  • Shaperon Inc
  • Shulov Innovative Science Ltd
  • Sienna Biopharmaceuticals Inc
  • Signum Biosciences Inc
  • Signum Dermalogix Inc
  • Sosei Heptares
  • Spherium Biomed SL
  • StemRIM Inc
  • sterna biologicals Gmbh & Co KG
  • Suzhou Connect Biopharmaceuticals Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • Temisis Therapeutics
  • The Geneva Biotech Center SA
  • Therabest Co Ltd
  • Tianjin Hemay Bio-Tech Co Ltd
  • Tolerys SA
  • Torrent Pharmaceuticals Ltd
  • Transdermal Therapeutic Technologies LLC
  • Union Therapeutics AS
  • Vasomune Inc
  • VivaCell Biotechnology Espana SL
  • Voronoi
  • vTv Therapeutics Inc
  • Welichem Biotech Inc
  • XBiotech Inc
  • Xencor Inc
  • Zhejiang I-Biological Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll